Business Context and Reporting Period
This Form 6-K was filed by Novartis AG, a Swiss-based foreign private issuer, on February 14, 2017. The filing serves to incorporate by reference a specific financial exhibit into the company's Registration Statement on Form F-3 (File No. 333-207004).
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document solely references the inclusion of a "Statement of Computation of Ratio of Earnings to Fixed Charges" as Exhibit 12.3.
Material Changes
The filing text does not provide data regarding material changes versus prior comparable periods.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, guidance, outlook, risks, contingencies, or unusual items. The document is procedural in nature, focusing on the incorporation of an exhibit into a registration statement.
Investor Verification Checklist
- Verify the specific values within Exhibit 12.3 (Statement of Computation of Ratio of Earnings to Fixed Charges) which is referenced but not detailed in this text.
- Review the full Registration Statement on Form F-3 (File No. 333-207004) to understand the context of the securities offering.
- Confirm the identity of the signatory, Paul Penepent, Head of Group Financial Reporting and Accounting.